Orgenesis Stock Book Value Per Share
ORGSDelisted Stock | USD 1.22 0.31 20.26% |
Orgenesis fundamentals help investors to digest information that contributes to Orgenesis' financial success or failures. It also enables traders to predict the movement of Orgenesis OTC Stock. The fundamental analysis module provides a way to measure Orgenesis' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Orgenesis otc stock.
Orgenesis |
Orgenesis OTC Stock Book Value Per Share Analysis
Orgenesis' Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
More About Book Value Per Share | All Equity Analysis
Book Value per Share | = | Common EquityAverage Shares |
Current Orgenesis Book Value Per Share | (3.30) X |
Most of Orgenesis' fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Orgenesis is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
CompetitionIn accordance with the recently published financial statements, the book value per share of Orgenesis is about -3.303 times. This is 94.29% higher than that of the Biotechnology sector and 98.67% lower than that of the Health Care industry. The book value per share for all United States stocks is 100.17% higher than that of the company.
Orgenesis Book Value Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Orgenesis' direct or indirect competition against its Book Value Per Share to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Orgenesis could also be used in its relative valuation, which is a method of valuing Orgenesis by comparing valuation metrics of similar companies.Orgenesis is currently under evaluation in book value per share category among its peers.
Orgenesis Fundamentals
Return On Equity | -7.27 | ||||
Return On Asset | -0.3 | ||||
Operating Margin | (16.54) % | ||||
Current Valuation | 23.01 M | ||||
Shares Outstanding | 4.77 M | ||||
Shares Owned By Insiders | 21.16 % | ||||
Shares Owned By Institutions | 4.54 % | ||||
Number Of Shares Shorted | 56.25 K | ||||
Price To Earning | 7.52 X | ||||
Price To Book | 1.26 X | ||||
Price To Sales | 15.21 X | ||||
Revenue | 530 K | ||||
Gross Profit | 36.02 M | ||||
EBITDA | (54.07 M) | ||||
Net Income | (64.92 M) | ||||
Cash And Equivalents | 2.3 M | ||||
Cash Per Share | 0.09 X | ||||
Total Debt | 22.62 M | ||||
Debt To Equity | 0.64 % | ||||
Current Ratio | 1.57 X | ||||
Book Value Per Share | (3.30) X | ||||
Cash Flow From Operations | (14.84 M) | ||||
Short Ratio | 2.39 X | ||||
Earnings Per Share | (8.00) X | ||||
Target Price | 6.0 | ||||
Number Of Employees | 146 | ||||
Beta | 1.21 | ||||
Market Capitalization | 10.07 M | ||||
Total Asset | 14.55 M | ||||
Retained Earnings | (176.62 M) | ||||
Working Capital | (12.33 M) | ||||
Current Asset | 5.29 M | ||||
Current Liabilities | 14.92 M | ||||
Net Asset | 14.55 M |
About Orgenesis Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Orgenesis's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Orgenesis using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Orgenesis based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as various price indices. Note that the Orgenesis information on this page should be used as a complementary analysis to other Orgenesis' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Other Consideration for investing in Orgenesis OTC Stock
If you are still planning to invest in Orgenesis check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Orgenesis' history and understand the potential risks before investing.
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |